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Abstract. COVID-19 is an emerging disease threatening the lives of patients and healthcare workers (HCWs) alike. In
this article, we present initial results of COVID-19 screening performed among the hospital staff of an infectious diseases
referral hospital in Manila, the Philippines. Of 324 HCWs tested, eight were positive; only one was exposed to COVID-19
patients,whereas sevenothers belonged to twodifferent departments. Routine screeningof hospital staff is invaluable for
the safety of the HCWs and the patients in hospitals and should be performed on a regular basis. Inmonitoring HCWs, we
protect one of our most valuable assets against COVID-19.
INTRODUCTION
COVID-19, caused by SARS-CoV-2, has spread to almost
every region and country of the world. Frontline healthcare
workers (HCWs) are at particular risk. A large number of HCWs
havealready been infected, and someof themhadalready lost
their lives. The International Council of Nurses estimated that
more than 90,000 HCWs had been infected worldwide.1 In the
Philippines, there were already 2,710 COVID-19–confirmed
cases among HCWs as of June 6, 2020.2 Protecting hospital
frontline staff is vital to sustain the operation of the hospital
and provision of health care to patients. In this article, we
describe our experience of screening HCWs in San Lazaro
Hospital (SLH), a tertiary referral hospital for infectious dis-
eases inManila, the Philippines, where the first two COVID-19
cases in the Philippines were confirmed on January 31, 2020
and February 1, 2020, respectively.3
The first laboratory-confirmed COVID-19 case of a HCW in
SLHwas reported onMarch 20, 2020. This led to great anxiety
and fear among HCWs in the hospital. At this time, however,
COVID-19 diagnostic testing was only available at the Re-
search Institute for Tropical Medicine, the national reference
laboratory, for individuals fulfilling the following criteria1:
presence of fever and/or cough, shortness of breath or other
respiratory symptoms, and2 travel or residence in an area
with local transmission of COVID-19, or close contact with a
confirmed COVID-19 case. Close contact was defined as
providing direct care without appropriate personal pro-
tective equipment (PPE), staying in the same close envi-
ronment, and traveling together in close proximity (1 m) in
any kind of conveyance.4
To support hospital operations with infection control mea-
sures against further spread, COVID-19 screening for hospital
staff was initiated at theSLH-Nagasaki UniversityCollaborative
Research Laboratory (SLH-NU) on the same day that the first
HCW case was detected. Screening activities were imple-
mented under an existing epidemiological research study on
COVID-19 in SLH with ethical approval from the SLH research
ethics and review unit (Ref: SLH-RERU-2020-022-I) and the
School of Tropical Medicine and Global Health, Nagasaki Uni-
versity Ethical Committee (NU_TMGH_2020_119_1).
MECHANISMS OF SCREENING
Screening activities were prioritized among HCWs who
were in close contact with the first COVID-positive case.
Subsequently, a clinic responsible for the hospital staff health
was designated to identify HCWs for screening. Hospital staff
with known COVID-19 exposure or related signs and symp-
toms received consultation at the clinic and were referred to
the SLH-NU for testing. The criteria for referral for testing were
as follows: 1) history of close contact or high-risk exposure
with a confirmed COVID-19 case as defined by the WHO
Global Surveillance for COVID-195 or 2) development of
COVID-related signs and symptoms.
Risk assessment was performed according to the CDC
guideline.6 High-risk exposure was defined as 1) prolonged
close contact of a HCW with a COVID-19 patient while both
the HCW and patient were without face masks; or 2) same-
room exposure to aerosolizing procedures on a COVID-19
patient while the HCW was without a face mask or goggles.
Medium-risk exposure was defined as 3) prolonged close
contact with a COVID-19 patient with face mask while the
HCW was not wearing a mask or goggles; or 4) prolonged
close contact with a patient while the HCW was wearing a
gown, gloves, eye protection, and a face mask (versus respi-
rator) during an aerosol generating procedure. Low-risk ex-
posure was defined as 5) brief interactions with a COVID-19
patient or 6) prolonged close contact with a patient wearing a
cloth mask/face mask while the HCW was wearing a face
mask or respirator.
Both nasopharyngeal and oropharyngeal swab specimens
were obtained using HydraFlock Sterile Flocked Collection
Devices (Puritan®, Guilford, ME). Viral RNAwas extracted and
purified from the specimen using QIAamp® Viral RNA Mini Kit
(Qiagen, Hilden, Germany). The RNA extracts were tested
using real-time reverse transcriptase PCR (rRT-PCR) for the
presence of SARS-CoV-2 viral RNA using primers and probes
from Corman et al.7 and Nao et al.8 protocols. Synthesized
oligonucleotides were used as positive controls. Primers and
probes todetectRnasePwere usedas internal control. In each
run, a no-template control containing only themastermix with
PCR-grade water was added. Samples for rRT-PCR were
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placed in single tubes. Viral RNA extraction, reagent prep-
aration for rRT-PCR, and addition of template RNA were
performed in separate rooms using previously decontami-
nated and ultraviolet-irradiated class II type A2 biosafety
cabinets.
We summarized demographic characteristics, comorbidities,
and signs and symptoms by whether screened cases tested
positive or not. Continuous variables were expressed as mean
(SD) and median (range), and categorical variables were
expressed as number (%). Fisher’s exact test was used to test
for associations between categorical variables, and the Mann–
Whitney test was used to compare discrete variables between
categoriesof categorical variables.All analyseswereconducted
using Stata v. 15 (StataCorp LLC, College Station, TX).
RESULTS
From March 20 to April 20, 324 COVID-19 PCR tests were
performed from SLH’s 1,213 HCW staff (141 doctors, 299
nurses, 198 nursing aides, 90 clinical staff, and 485 nonclinical
employees and administrators) at the SLH-NU laboratory (see
Supplemental Table 1). Of 324 tests, 97 were categorized as
moderate- or high-risk exposure, whereas 227 were low risk.
The difference between the date of symptom onset and the
date of swab collection was amedian of 6 days and amean of
5 days for symptomatic participants. Most of those tested
were female (216, 67%) and aged between 30 and 39 years
(140, 43%). Eight of 324 (2%) tested positive via rRT-PCR for
SARS-CoV-2 infection. Most of the HCWs tested were nurses
(203, 63%), followed by nursing aides (61, 19%), medical
doctors (37, 11%), laboratory personnel (12, 4%), and radi-
ology technicians (6, 2%).
Four (50%) of the COVID-19–positive HCWsbelonged to the
30- to 39-year age-group. Six were female (75%). Four were
nurses (50%), three were laboratory personnel (38%), and one
was a medical doctor (13%). One had asthma (13%), diabetes
(13%), hypertension (13%), and dyslipidemia (13%). Another
one had obesity (13%). Six had no comorbidities (75%).
Of the eight positives, only one, a 31/F nurse,wasmanaging
patients on a COVID-19 ward. She was classified to have low-
risk exposure because of proper PPE use during interactions
with patients. Seven others belonged to two different hospital
departments. The first group consisted of a 48/M infectious
diseasephysician andhis nurses, a 32/F anda30/M,whoboth
lived in the same apartment during the community quarantine
period. All three of themwere part of a clinical teammanaging
tuberculosis (TB) patients. These patients subsequently
tested negative for SARS-CoV-2 after screening.9 The said
physician who first developed COVID-19–like signs and
symptoms had low-risk exposure to COVID-19 patients. The
nurses, however, were classified to have high-risk un-
protected exposure to the doctor, who was eventually con-
firmed COVID-19 positive. Seventeen days after the last
COVID-19–positive HCW from the TB ward was detected,
another nurse, 32/F, tested positive.
The second group consisted of medical technologists
(24/F, 23/F, and 42/F), who lived together during the com-
munity quarantine period inManila andwere working in SLH’s
HIV clinic. They were initially classified to have low-risk ex-
posure with symptoms. However, during contact tracing, it
was discovered that one of their housemates developed
symptoms a few days before they were screened.
Seven of eight of the positive HCWs presented with re-
spiratory symptoms such as cough (5), sore throat (4), rhinor-
rhea (3), andshortness of breath (1). Non-respiratory symptoms
included loss of taste (3), loss of smell (3), loss of appetite (2),
fever (1), vomiting (1), headache (5), nausea (1), chills (1), joint
ache (1), and muscle ache (1). Other symptoms reported were
diarrhea (1) and fatigue (1). Two reported no symptoms. Of all
thesesymptoms, only loss of smell (P=0.004), loss of taste (P=
0.003), and loss of appetite (P = 0.02) were associated with
confirmed COVID-19.
DISCUSSION
Among the 324 HCWs we screened for COVID-19, eight
were positive, and only one had worked in a COVID-19 ward.
The number of COVID-19 cases among HCWs in this study
represents a small number compared with the Philippines’
total of 2,710 HCWs.2 Although the number of COVID-19–
positive HCWs in our study is small, some comparison with
other studies is possible. In a study of HCWs in a tertiary
hospital in Wuhan, China, 72% of 110 COVID-19–positive
HCWswere females, with amedian age of 36.5 years.10 This is
similar to our study where six of eight of the COVID-19–
positive HCWswere females and four of eight belonged to the
30- to 39-year age-group. The same study reported that 56%
and 24% of the affected HCWs were nurses and physicians,
respectively, and 66% of the COVID-19–positive HCWs were
not tending to COVID-19 patients.10 In our screening, half of
the positive hospital staff were nurses, followed by laboratory
personnel, and only one was a physician. All except one of the
positive HCWs were assigned to non–COVID-19 areas. Fur-
ther analysis such as sequencing of the SARS-CoV-2 viromes
from the affected HCWs could be pursued in the future to
investigate epidemiological links among COVID-19–positive
individuals.
Another study from a hospital in Wuhan reported that my-
algia (100%), fever (86%), dry cough (71%), diarrhea (64%),
headache (57%), and pharyngalgia (50%) were the most
common symptoms among 12 COVID-confirmed HCWs.11 In
our study, headache, cough, and sore throat were also among
themost common. However, loss of taste, smell, and appetite
were the only symptoms significantly associated with being
COVID-19 positive.
The timely and effective infection prevention and control
(IPC) measures of the hospital have potentially contained fur-
ther transmission of COVID-19 to other susceptible HCWs, but
these measures need to be sustained. Early preparations for
COVID-19were prompted by the arrival of the first two cases in
SLH in late January, over a month before community trans-
mission was announced in Manila in March. By February, a
COVID-19 triage was set up at the entrance of the hospital to
screen for COVID-19 signs and symptoms among patients ar-
riving at the hospital. This allowed each patient to be managed
and isolated, if needed, while the HCWs wore proper PPE.
A study of affected HCWs from a university hospital in
Wuhan, China, observed a large difference in hospital IPC be-
fore and after the outbreak.12 Before the outbreak, only 78% of
HCWs strictly followed hand hygiene, 53% strictly followed
proper donning and doffing of PPE, 66% always wore masks,
and 52% wore gloves in routine work. Seventy-seven percent
of the hospital staff believed that the lack of appropriate PPE
caused their infection.12
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In SLH, before assignment of HCWs to COVID-19 areas,
knowledge on the proper use of PPE was ensured by
reorienting them on already standard hospital practices on
donning and doffing. Despite challenges with resources in
the months after March, the hospital was able to conserve
their PPEs by implementingmodified hospital guidelines on
PPE use. This allowed the staff in non–COVID-19 areas to
use less PPEs depending on the level of risk in the hospital
areas they were assigned to. For example, in the COVID
triage area, nurses who screen patients only wear a face
mask and goggles/face shield, and doctors who assess
patients only wear a disposable gown, N95 mask, and
gloves.
Another study from Wuhan reported that psychosocial or
emotional stressors of HCWs during the time of COVID-19
included disease-related issues (81%), worry about fami-
lies’ health, and negative Internet news (40%).12 At SLH,
HCWs were provided with regular briefing and de-briefing
sessions with the hospital psychologist for mental health
support. This was designed to address their worries and
anxieties, particularly those stemming from occupational
exposure to COVID-19.
San Lazaro Hospital’s patient safety office and the admin-
istrators of each department ensured regular assessment
among HCWs for breaches in IPC protocols while being ex-
posed toCOVID-19 patients. Hospital staff were also routinely
evaluated for the development of respiratory signs and symp-
toms. Thosewhoneededmedical attentionwere referred to the
employees’ medical clinic.
CONCLUSION
Early initiation of COVID-19 screening for HCWs and the
preparation for the outbreak may have reduced the risk of
infection in SLH. These practices allowed SLH to continue to
provide hospital care for their patients. Healthcareworkers are
not only at risk of contractingCOVID-19 frompatients but also
pose risks to immunocompromised patients if they are in-
fected. Toprevent andcontrol COVID-19 transmission, HCWs
should be closely monitored and examined routinely in an
accessible clinic dedicated for hospital staff. Screening for
SARS-CoV-2 infection should also bemade available for them
and should be performed on a regular basis. The reported
seven cases of COVID-19 identified among HCWs in the
course of the epidemic highlight the importance of such rec-
ommendations. In monitoring HCWs, we protect one of our
most valuable assets against COVID-19.
Received June 22, 2020. Accepted for publication July 16, 2020.
Published online July 29, 2020.
Note: Supplemental table appears at www.ajtmh.org.
Acknowledgments: We would like to acknowledge San Lazaro Hos-
pital’s Infection Control and Prevention Office, Patient Safety Office,
and Employees Medical Clinic for their contributions to the imple-
mentation of this study. We also thank SLH-Nagasaki University
Collaborative Research Office team for their dedication in data col-
lection, as well Taichiro Takemura and Shingo Inoue of Nagasaki
University for their guidance in the development of the methods used
in this study.Publicationcharges for this articlewerewaiveddue to the
ongoing pandemic of COVID-19.
Financial support: This work was in part funded by Nagasaki Univer-
sity (salary support for A.M.G. V., S. H.M., T.U., S. S., K. A., andC. S.).
Disclaimer: The funder of the study had no role in the study design,
data collection, data analysis, data interpretation or the writing of the
report. The corresponding author had full access to all the data in the
study and had final responsibility for the decision to submit for
publication.
Disclosure: Informedconsentwasobtained fromall studyparticipants
enrolled to this study. This research was reviewed and approved by
the San Lazaro Hospital-Research Ethics and Review Unit (Ref: SLH-
RERU-2020-022-I) and the School of Tropical Medicine and Global
Health, Nagasaki University ethical committee (NU_TMGH_2020_
119_1).
Authors’ addresses: Annavi Marie G. Villanueva and Shuichi Suzuki,
San Lazaro Hospital – Nagasaki University Collaborative Research
Office, Manila, Philippines, and School of Tropical Medicine and
Global Health, Nagasaki University, Nagasaki, Japan, E-mails:
agvillanueva@up.edu.ph and suzuki_shuichi@nagasaki-u.ac.jp. Jez-
reel Lazaro, Ana Ria Sayo, Elizabeth Telan, and Rontgene Solante,
San Lazaro Hospital, Manila, Philippines, E-mails: jez_lazaro@
yahoo.com, anariasayo@yahoo.com, betelan@yahoo.com, and
rontgenesolante@gmail.com. Su Myat Han and Tatsuya Ukawa,
School of Tropical Medicine and Global Health, Nagasaki University,
Nagasaki Japan, E-mails: pearl.june@gmail.com and t_rrss_thx@
yahoo.co.jp. Saho Takaya and Chris Smith, School of Tropical Med-
icine and Global Health, Nagasaki University, Nagasaki Japan, and
Faculty of Infectious and Tropical Diseases, London School of Hy-
giene andTropicalMedicine, London, England, E-mails: sahotakaya@
gmail.com and christopher.smith@lshtm.ac.uk. Koya Ariyoshi, In-
stitute of Tropical Medicine, Nagasaki University, Nagasaki, Japan,
E-mail: koya.ariyoshi@gmail.com.
This is an open-access article distributed under the terms of the
Creative Commons Attribution (CC-BY) License, which permits un-
restricted use, distribution, and reproduction in anymedium, provided
the original author and source are credited.
REFERENCES
1. International Council of Nurses, 2020. ICN Calls for Data on
Healthcare Worker Infection Rates and Deaths. Geneva, Swit-
zerland: International Council of Nurses. Available at: https://
www.icn.ch/news/icn-calls-data-healthcare-worker-infection-
rates-and-deaths. Accessed May 22, 2020.
2. Department of Health, 2020. Beat COVID-19 Today: A COVID-19
Philippine Situationer, 40. Manila, Philippines: Department of
Health.
3. Edrada EM et al., 2020. First COVID-19 infections in the Philip-
pines: a case report. Trop Med Health 48: 21.
4. Department of Health, 2020. Algorithm for Triage of Patients with
Possible COVID-19 Infection in Health Care Facilities. Manila,
Philippines: Department of Health. Available at: https://www.
doh.gov.ph/sites/default/files/Updated_Decision_Tool_March_
16.pdf. Accessed May 15, 2020.
5. World Health Organization. 2020. Global Surveillance for
COVID-19 Caused by Human Infection with COVID-19
Virus. Geneva, Switzerland: WHO. Available at: https://
www.who.int/docs/default-source/coronaviruse/global-
surveillance-for-covid-v-19-final200321-rev.pdf. Accessed
April 29, 2020.
6. CDC, 2020. Interim U.S. Guidance for Risk Assessment and
Public Health Management of Healthcare Personnel with
Potential Exposure in a Healthcare Setting to Patients with
Coronavirus Disease 2019 (COVID-19). Atlanta, GA: CDC.
Available at: https://www.cdc.gov/coronavirus/2019-ncov/
hcp/guidance-risk-assesment-hcp.html. Accessed May 19,
2020.
7. Corman VM et al., 2020. Detection of 2019 novel coronavirus
(2019-nCoV) by real-time RT-PCR. Eurosurveillance 25.
Available at: https://doi.org/10.2807/1560-7917.ES.2020.25.
3.2000045.
8. Nao N. et al., 2020. Detection of second case of 2019-nCoV
infection in Japan. Problem Set 2 23: 1–9. Available at:
https://doi.org/1037//0033-2909.I26.1.78.
COVID-19 SCREENING FOR HCWS IN A HOSPITAL IN MANILA 3
9. Sayo AR, Balinas EGM, Verona JA, Villanueva AMG, Han SM,
Suzuki J, Ariyoshi K, Smith C, Solantea RM, 2020. COVID-19
screening on a tuberculosis ward in Manila, the Philippines.
J Clin Tuberc Other Mycobact Dis 20: 100167.
10. Lai X et al., 2020. Coronavirus disease 2019 (COVID-2019) in-
fection among health care workers and implications for pre-
vention measures in a tertiary hospital in Wuhan, China. JAMA
Netw Open 3: e209666.
11. Wei XS et al., 2020. A cluster of health care workers with COVID-
19 pneumonia caused by SARS-CoV-2. J Microbiol Immunol
Infect. Available at: https://doi.org/10.1016/j.jmii.2020.04.013.
12. Jin YH et al., 2020. Perceived infection transmission routes, in-
fection control practices, psychosocial changes and manage-
ment of COVID-19 infected healthcare workers in a tertiary
acute care hospital inWuhan: a cross-sectional survey.MilMed
Res 7: 24.
4 VILLANUEVA AND OTHERS
Supplementary table
Table  1.  Characteristics  of  324healthcare  workers  from  San  Lazaro  Hospital  screened  for
COVID-19
Characteristics All Covid-19 Non-Covid p-value
Overall  324 8 316  
Age (years) N 324 8 316  
 mean (SD) 36 (9) 33 (8) 36 (9)  
 median (range) 32 (23, 63) 31.5 (23, 48)
32 (23, 
63) 0.39
Age group (years)
 20-29 88 (27) 2 (25) 86 (27)  
 30-39 140 (43) 4 (50) 136 (43)  
 40-49 68 (21) 2 (25) 66 (21)  
 50-59 24 (7)  24 (8)  
 60-69 4 (1)  4 (1)  
Sex
 Female 216 (67) 6 (75) 210 (66) 0.72
 Male 108 (33) 2 (25) 106 (34)  
Occupation
Nurse 203 (63) 4 (50) 199 (63)
Medical doctor 37 (11) 1 (13) 36 (11)
Nursing aide 61 (19) 61 (19)
Radiology 
technician 6 (2) 6 (2)
Laboratory 
personnel 12 (4) 3 (38) 9 (2)
Clerk 4 (1) 4 (1)
Other HCW 1 1
Level of Exposure 
 Low Risk 227 (70) 4 (50) 223 (71) 0.25
 High Risk 97 (30) 4 (50) 93 (29)  
Signs and symptoms  
Fever No 320 (99) 7 (88) 313 (99)  
 Yes 4 (1) 1 (12) 3 (1) 0.1
Cough No 157 (48) 3 (38) 154 (49) 0.76
 Yes 161 (50) 5 (62) 156 (49)  
Sore throat No 100 (31) 4 (50) 96 (30) 0.37
 Yes 217 (67) 4 (50) 213 (67)  
Running nose No 191 (59) 5 (62) 186 (59) 1
 Yes 126 (39) 3 (38) 123 (39)  
Shortness of breath No 287 (89) 8 (100) 279 (88) 1
 Yes 28 (9)  28 (9) 1
 Loss of smell No 241 (74) 4 (50) 237 (75) 0.004
 Yes 13 (4) 3 (38) 10 (3)  
Loss of taste No 241 (74) 4 (50) 237 (75) 0.003
 Yes 12 (4) 3 (38) 9 (3)  
Conjunctivitis No 320 (99) 8 (100) 312 (99) 1
 Yes 4 (1)  4 (1)  
Diarrhea No 282 (87) 7 (88) 275 (87) 1
 Yes 42 (13) 1 (12) 41 (13)  
Fatigue No 269 (83) 7 (88) 262 (83) 1
 Yes 55 (17) 1 (12) 54 (17)  
Malaise No 312 (96) 8 (100) 304 (96) 1
 Yes 12 (4)  12 (4)  
Headache No 185 (57) 3 (38) 182 (58) 0.3
 Yes 139 (43) 5 (62) 134 (42)  
Joint pains No 291 (90) 7 (88) 284 (90) 0.52
 Yes 33 (10) 1 (12) 32 (10)  
Loss of appetite No 314 (97) 6 (75) 308 (97) 0.02
 Yes 10 (3) 2 (25) 8 (3)  
Muscle pain No 245 (76) 7 (88) 238 (75) 0.69
 Yes 79 (24) 1 (12) 78 (25)  
Epistaxis No 320 (99) 8 (100) 312 (99) 1
 Yes 4 (1)  4 (1)  
Rash No 320 (99) 8 (100) 312 (99) 1
 Yes 4 (1)  4 (1)  
Vomiting No 319 (98) 7 (88) 312 (99) 0.12
 Yes 5 (2) 1 (12) 4 (1)  
Chills No 309 (95) 7 (88) 302 (96) 0.32
 Yes 15 (5) 1 (12) 14 (4)  
Nausea No 310 7 (87.5) 303 (96) 0.3
 Yes 14 1 (12.5) 13 (4)  
Comorbidities      
Asthma No 301 (93) 7 (88) 294 (93) 0.449
 Yes 23 (7) 1 (12) 22 (7)  
Cancer No 322 (99) 8 (100) 314 (99) 1
 Yes 2 (1)  2 (1)  
Chronic Kidney Disease No 321 (99) 8 (100) 313 (99) 1
 Yes 3 (1)  3 (1)  
Chronic Liver Disease No 323 (100) 8 (100)
315 
(100) 1
 Yes 1 (0)  1 (0)  
Diabetes No 298 (92) 7 (88) 291 (92) 0.492
 Yes 26 (8) 1 (12) 25 (8)  
Heart disease No 316 (98) 8 (100) 308 (97) 1
 Yes 8 (2)  8 (3)  
Hypertension No 257 (79) 7 (88) 250 (79) 1
 Yes 67 (21) 1 (12) 66 (21)  
Obesity No 267 (82) 7 (88) 260 (82) 1
 Yes 57 (18) 1 (12) 56 (18)  
Dyslipidemia No 323 (100) 7 (88)
316 
(100) 0.025
 Yes 1 (0) 1 (12)   
At least one underlying 
disease No 5 (2)  5 (2) 1
 Yes 319 (98) 8 (100) 311 (98)  
Duration between onset of 
symptoms and swab 
collection (within 14 days)
N 244 7 237 0.298
 mean (SD) 6 (3) 7 (3) 6 (3)  
 median (range) 6 (0, 14) 8 (0, 14) 5 (0, 14)  
